Phase 1/2 × Interventional × Gynecologic × Clear all
NCT06239194 2026-05-06

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Recruiting
285 enrolled
NCT06128551 2026-04-23

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
534 enrolled